lipogenesis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Secondary cold agglutinin disease === Secondary cold agglutinin syndrome occurs when autoantibodies bind to red blood cells, rendering them subject to attack by the complement system. It is a result of an underlying condition potentially associated with either monoclonal cold-reacting autoantibodies or polyclonal cold-reacting autoantibodies predominantly caused by infection or lymphoproliferative disorders. In adults, this is typically due to:
Firstly, as revealed by computational chemistry studies, the unpaired electron is stabilized through delocalization by the aromatic ring of tyrosine and the cross-linked cysteine sulfur, with the oxygen atom of Tyr272 possessing high unpaired electron density. Some experimental evidence also suggests that axial Tyr495 is also involved in unpaired electron delocalization. Secondly, the indole ring of a tryptophan (Trp290) lies above and parallel to Tyrosine-Cysteine, behaving like a shield protecting the radical from the external solvent environment. Supporting evidence comes from that mutation of this tryptophan residue leads to a lower stability of the active form of galactose oxidase. Additionally, the outer sphere of the active site consists of many aromatic residues that give the active site a hydrophobic character. There are also extensive hydrogen bonding networks surround the active site.
There are production and distribution bottlenecks, plan failures, consumer scarcities, criminal abuses of power, suppression of dissidents, and expressions of alienation among some of the population." Parenti further argued that the economies of Eastern European countries and the Soviet Union suffered from "fatal distortions in their development" because of "embargo[s], invasion, devastating wars, and costly arms buildup; excessive bureaucratization and poor incentive systems; lack of administrative initiative and technological innovation; and a repressive political rule that allowed little critical expression and feedback while fostering stagnation and elitism." In Western Europe, communist parties, which were still committed to Marxism–Leninism through more democratic means, were part of the initial post-war governments, and even when the Cold War forced many of those countries to remove them from government, such as in Italy, they remained part of the liberal-democratic process. By the 1960s and 1970s, many Western Marxist–Leninists had criticised many of the actions of Communist states, distanced from them, and developed a democratic road to socialism, which became known as Eurocommunism. This development was criticised by both non-Marxist–Leninists and other Marxist–Leninists in the East as amounting to social democracy.
== Early life and education == Bibudhendra Sarkar was born on August 2, 1935, in Kushtia, Bengal, British India (now Bangladesh). His father, Surendra Nath Sarkar, was a lawyer, and his mother, Sucheta Sarkar (née Chaki), a homemaker, died when he was one year old. He completed his kindergarten and primary education at Kushtia Mission School, a Catholic institution. Following the Partition of India in 1947, Sarkar's family relocated to Calcutta after losing their possessions. He attended City College School and later City College, Kolkata, earning his Matriculation and Intermediate Science certifications from the University of Calcutta. He pursued higher education at Banaras Hindu University in Uttar Pradesh, specializing in the chemistry of natural products and earning Bachelor of Pharmacy (B.Pharm) and Master of Pharmacy (M.Pharm) degrees. During his undergraduate studies, Sarkar worked as a summer researcher at the Central Drug Research Institute in Lucknow, under the mentorship of Manojit Mohan Dhar, who encouraged him to pursue graduate studies abroad. He subsequently moved to the United States, completing a PhD in biochemistry at the University of Southern California in 1964 under the supervision of Paul Saltman. At USC, his work was influenced by chemists Sydney Benson (chemical kinetics), Arthur Adamson (physical chemistry), and Bo Malmström (metal-activated enzyme chemistry).
Sources: en.wikipedia.org
== Discovery and naming == The name renin = ren + -in, "kidney" + "compound". The most common pronunciation in English is (long e); (short e) is also common, but using allows one to reserve for rennin. Renin was discovered, characterized, and named in 1898 by Robert Tigerstedt, Professor of Physiology, and his student, Per Bergman, at the Karolinska Institute in Stockholm.
== Interleukin antagonists == Interleukins are a cytokine that play a major role in the immune system. IL-12 and IL-23 help with the activation and differentiation of natural killer cells and CD4+ T lymphocyte, both of which contribute to inflammation. Interleukin antagonists, the most recent class of biologics available for use in IBD, inhibit the action of IL-12 and IL-23 by binding to the p40 protein subunit that is found on both of these cytokines.
=== Even electron rule === The even electron rule states that ions with an even number of electrons (cations but not radical ions) tend to form even-electron fragment ions and odd-electron ions (radical ions) form odd-electron ions or even-electron ions. Even-electron species tend to fragment to another even-electron cation and a neutral molecule rather than two odd-electron species.
Air cargo refers to any goods shipped by air, whereas air freight refers specifically to goods transported in the cargo hold of a dedicated cargo plane. Aircraft were first used to carry mail as cargo in 1911. Eventually manufacturers started designing aircraft for other types of freight as well. There are many commercial aircraft suitable for carrying cargo such as the Boeing 747 and the more prominent An‑124, which was purposely built for easy conversion into a cargo aircraft. Such large aircraft employ standardized quick-loading containers known as unit load devices (ULDs), comparable to ISO containers on cargo ships. ULDs can be stowed in the lower decks (front and rear) of several wide-body aircraft, and on the main deck of some narrow-bodies. Some dedicated cargo planes have a large opening front for loading. Air freight shipments are very similar to LTL shipments in terms of size and packaging requirements. However, air freight or air cargo shipments typically need to move at much faster speeds than 800 km or 497 mi per hour. While shipments move faster than standard LTL, air shipments do not always actually move by air. Air shipments may be booked directly with the carriers, through brokers or with online marketplace services. In the US, there are certain restrictions on cargo moving via air freight on passenger aircraft, most notably the transport of rechargeable lithium-ion battery shipments. Shippers in the US must be approved and be "known" in the Known Shipper Management System before their shipments can be tendered on passenger aircraft.
Freezer burn is a condition that occurs when frozen food has been damaged by dehydration and oxidation due to air reaching the food. It is generally caused by food not being securely wrapped in air-tight packaging. Freezer burn appears as grayish-brown leathery spots on frozen food and occurs when air reaches the food's surface and dries the product. Color changes result from chemical changes in the food's pigment. Freezer burn does not make the food unsafe; it merely causes dry spots in foods. The food remains usable and edible, but removing the freezer burns can improve the flavor. The dehydration of freezer-burned food is caused by water sublimating from the food into the surrounding atmosphere. The lost water may then be deposited elsewhere in the food and packaging as snow-like crystals. Fluctuation of temperatures in a freezer, such that the temperature does not remain consistently below −18 °C, can also speed up freezer burn.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.